vs

Side-by-side financial comparison of BWX Technologies, Inc. (BWXT) and Privia Health Group, Inc. (PRVA). Click either name above to swap in a different company.

BWX Technologies, Inc. is the larger business by last-quarter revenue ($885.8M vs $541.2M, roughly 1.6× Privia Health Group, Inc.). BWX Technologies, Inc. runs the higher net margin — 10.5% vs 1.7%, a 8.8% gap on every dollar of revenue. On growth, BWX Technologies, Inc. posted the faster year-over-year revenue change (18.7% vs 17.4%). Over the past eight quarters, BWX Technologies, Inc.'s revenue compounded faster (21.1% CAGR vs 14.2%).

BWX Technologies, Inc. is a company headquartered in Lynchburg, Virginia that supplies nuclear components and fuel internationally.

Privia Health Group, Inc. is a U.S.-headquartered healthcare technology and services firm supporting independent practices, health systems, and payers delivering value-based care. It offers population health tools, patient engagement platforms, care coordination support, and workflow solutions to boost patient outcomes and cut operational costs for U.S. healthcare stakeholders.

BWXT vs PRVA — Head-to-Head

Bigger by revenue
BWXT
BWXT
1.6× larger
BWXT
$885.8M
$541.2M
PRVA
Growing faster (revenue YoY)
BWXT
BWXT
+1.3% gap
BWXT
18.7%
17.4%
PRVA
Higher net margin
BWXT
BWXT
8.8% more per $
BWXT
10.5%
1.7%
PRVA
Faster 2-yr revenue CAGR
BWXT
BWXT
Annualised
BWXT
21.1%
14.2%
PRVA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BWXT
BWXT
PRVA
PRVA
Revenue
$885.8M
$541.2M
Net Profit
$93.0M
$9.2M
Gross Margin
Operating Margin
10.4%
2.1%
Net Margin
10.5%
1.7%
Revenue YoY
18.7%
17.4%
Net Profit YoY
30.9%
108.0%
EPS (diluted)
$1.02
$0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BWXT
BWXT
PRVA
PRVA
Q4 25
$885.8M
$541.2M
Q3 25
$866.3M
$580.4M
Q2 25
$764.0M
$521.2M
Q1 25
$682.3M
$480.1M
Q4 24
$746.3M
$460.9M
Q3 24
$672.0M
$437.9M
Q2 24
$681.5M
$422.3M
Q1 24
$604.0M
$415.2M
Net Profit
BWXT
BWXT
PRVA
PRVA
Q4 25
$93.0M
$9.2M
Q3 25
$82.1M
$6.9M
Q2 25
$78.4M
$2.7M
Q1 25
$75.5M
$4.2M
Q4 24
$71.0M
$4.4M
Q3 24
$69.5M
$3.5M
Q2 24
$73.0M
$3.5M
Q1 24
$68.5M
$3.0M
Gross Margin
BWXT
BWXT
PRVA
PRVA
Q4 25
Q3 25
21.8%
Q2 25
25.1%
Q1 25
24.2%
Q4 24
Q3 24
24.4%
Q2 24
24.7%
Q1 24
24.6%
Operating Margin
BWXT
BWXT
PRVA
PRVA
Q4 25
10.4%
2.1%
Q3 25
13.1%
2.5%
Q2 25
13.4%
0.6%
Q1 25
14.2%
1.1%
Q4 24
12.4%
1.1%
Q3 24
14.4%
1.3%
Q2 24
14.5%
1.2%
Q1 24
15.4%
0.2%
Net Margin
BWXT
BWXT
PRVA
PRVA
Q4 25
10.5%
1.7%
Q3 25
9.5%
1.2%
Q2 25
10.3%
0.5%
Q1 25
11.1%
0.9%
Q4 24
9.5%
1.0%
Q3 24
10.3%
0.8%
Q2 24
10.7%
0.8%
Q1 24
11.3%
0.7%
EPS (diluted)
BWXT
BWXT
PRVA
PRVA
Q4 25
$1.02
$0.08
Q3 25
$0.89
$0.05
Q2 25
$0.85
$0.02
Q1 25
$0.82
$0.03
Q4 24
$0.77
$0.03
Q3 24
$0.76
$0.03
Q2 24
$0.79
$0.03
Q1 24
$0.75
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BWXT
BWXT
PRVA
PRVA
Cash + ST InvestmentsLiquidity on hand
$499.8M
$479.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.2B
$737.2M
Total Assets
$4.3B
$1.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BWXT
BWXT
PRVA
PRVA
Q4 25
$499.8M
$479.7M
Q3 25
$79.6M
$441.4M
Q2 25
$37.0M
$390.1M
Q1 25
$55.4M
$469.3M
Q4 24
$74.1M
$491.1M
Q3 24
$35.5M
$422.0M
Q2 24
$48.3M
$387.4M
Q1 24
$45.9M
$351.1M
Stockholders' Equity
BWXT
BWXT
PRVA
PRVA
Q4 25
$1.2B
$737.2M
Q3 25
$1.2B
$709.1M
Q2 25
$1.2B
$682.9M
Q1 25
$1.1B
$659.4M
Q4 24
$1.1B
$635.2M
Q3 24
$1.1B
$614.9M
Q2 24
$998.5M
$595.4M
Q1 24
$946.2M
$576.8M
Total Assets
BWXT
BWXT
PRVA
PRVA
Q4 25
$4.3B
$1.4B
Q3 25
$3.8B
$1.4B
Q2 25
$3.7B
$1.3B
Q1 25
$3.1B
$1.2B
Q4 24
$2.9B
$1.1B
Q3 24
$2.9B
$1.1B
Q2 24
$2.8B
$1.1B
Q1 24
$2.8B
$1.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BWXT
BWXT
PRVA
PRVA
Operating Cash FlowLast quarter
$127.0M
$127.5M
Free Cash FlowOCF − Capex
$56.8M
FCF MarginFCF / Revenue
6.4%
Capex IntensityCapex / Revenue
7.9%
Cash ConversionOCF / Net Profit
1.37×
13.93×
TTM Free Cash FlowTrailing 4 quarters
$295.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BWXT
BWXT
PRVA
PRVA
Q4 25
$127.0M
$127.5M
Q3 25
$143.2M
$52.0M
Q2 25
$159.0M
$8.0M
Q1 25
$50.6M
$-24.1M
Q4 24
$276.9M
$74.8M
Q3 24
$32.6M
$33.2M
Q2 24
$65.9M
$34.5M
Q1 24
$33.0M
$-33.1M
Free Cash Flow
BWXT
BWXT
PRVA
PRVA
Q4 25
$56.8M
Q3 25
$94.9M
Q2 25
$126.3M
Q1 25
$17.3M
Q4 24
$224.4M
Q3 24
$-7.7M
Q2 24
$35.5M
Q1 24
$2.6M
FCF Margin
BWXT
BWXT
PRVA
PRVA
Q4 25
6.4%
Q3 25
11.0%
Q2 25
16.5%
Q1 25
2.5%
Q4 24
30.1%
Q3 24
-1.1%
Q2 24
5.2%
Q1 24
0.4%
Capex Intensity
BWXT
BWXT
PRVA
PRVA
Q4 25
7.9%
Q3 25
5.6%
Q2 25
4.3%
Q1 25
4.9%
Q4 24
7.0%
Q3 24
6.0%
Q2 24
4.5%
Q1 24
5.0%
Cash Conversion
BWXT
BWXT
PRVA
PRVA
Q4 25
1.37×
13.93×
Q3 25
1.74×
7.58×
Q2 25
2.03×
2.97×
Q1 25
0.67×
-5.70×
Q4 24
3.90×
17.00×
Q3 24
0.47×
9.38×
Q2 24
0.90×
9.94×
Q1 24
0.48×
-11.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BWXT
BWXT

Nuclear Component Program$436.4M49%
Nuclear Manufacturing$134.8M15%
Cost Plus Fee$116.1M13%
Uranium And Nuclear Services$103.8M12%
Commercial Operations$49.0M6%
Commercial Operations Segment$33.7M4%
Transferred At Point In Time$1.3M0%

PRVA
PRVA

FFS Patient Care$364.4M67%
Capitated Revenue$71.4M13%
Shared Savings$46.9M9%
FFS Administrative Services$36.0M7%
Care Management Fee PMPM$20.0M4%
Other Revenue$2.5M0%

Related Comparisons